RecruitMe Clinical Trial

Phase 1/2 FIH Study of REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Patients With Relapsed or Refractory Multiple Myeloma
First in Human (FIH) Study of REGN5458 in Patients With Relapsed or Refractory Multiple Myeloma
Sponsor:Regeneron Pharmaceuticals, Inc
Enrolling:Male and Female Patients
Minimum Age:18 years old
IRB Number:AAAS2588
U.S. Government ID:NCT03761108
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information:

This study will look at the safety of a drug (REGN5458) in patients with multiple myeloma. It will also try to find out what the best dose of REGN5458 is and look for any signs that REGN5458 can help treat your cancer. REGN5458 is investigational, which means it has not been approved by the US Food and Drug Administration (FDA) for any condition.

Do You Qualify?
Are you at least 18 years old?YesNo
Have you been diagnosed with Multiple Myeloma?YesNo
Has your disease progressed?YesNo
Submit
Cancel
Investigator
Suzanne Lentzsch, MD
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Research Nurse Navigator
Email: cancerclinicaltrials@cumc.columbia.edu
Phone: 212-342-5162